BDSI


BioDelivery: Clonidine Gel Is Significantly Undervalued By Investors, Says Roth Capital

In a research note published yesterday, Roth Capital analyst Scott Henry reiterated a Buy rating on BioDelivery Sciences (BDSI) with a $16.50 price …

William Blair Maintains Outperform On BioDelivery Following Positive Phase III Results

In a research report published Monday, William Blair analyst Tim Lugo maintained an Outperform rating on BioDelivery Sciences International Inc. (BDSI) and raised …

Roth Capital Sees 90% Probability Of BioDelivery’s Buprenorphine Approval

In a research note released this morning, Roth Capital analyst Scott Henry maintained a Buy rating on BioDelivery Sciences (BDSI) and raised his price target …

William Blair Maintains Outperform On BioDelivery Sciences

William Blair today maintained an Outperform rating on BioDelivery Sciences (BDSI) with $23.00 price target, which is derived through a net present value analysis …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts